Dr. Giugliano, MD is a Senior Investigator with the TIMI Study Group, Staff Physician in the Cardiovascular Division at Brigham and Women’s Hospital, and Associate Professor of Medicine at Harvard Medical School.
He graduated Summa Cum Laude, Phi Beta Kappa (Mathematics) from Dartmouth College (1985), receiving a medical degree at Harvard Medical School (1989). Dr. Giugliano completed residency and chief residency at Cedars-Sinai Medical Center (UCLA affiiliate,1989-93) and cardiology fellowship at Massachusetts General Hospital (1993-6).
In 1996, Dr. Giugliano joined the Brigham and Women’s Hospital as a Medicine Research Fellow in the Thrombolysis in Myocardial Infarction (TIMI) Study Group directed by Eugene Braunwald, and completed a Science Masters (Epidemiology) at the Harvard School of Public Health. In 1997, he joined the Cardiovascular Division faculty of the Brigham and Women’s Hospital and has served as the principal investigator for 9 multicenter clinical trials at TIMI.
His areas of research interests include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes (ACS). He has authored more than 400 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the Principal Investigator for the VESALIUS-CV trial of the PCSK9 inhibitor evolocumab in patients at high risk for cardiovascular events with no prior MI or stroke, and also the ENGAGE-AF TIMI 48 trial of the factor Xa inhibitor edoxaban in 21,105 patients with fibrillation. He is also a member of the Operations Committees and Lead TIMI Investigator for the FOURIER trial studying evolocumab in 27,564 hyperlipidemic patients with prior cardiovascular disease; the IMPROVE-IT trial evaluating ezetimibe in 18,144 patients post ACS; and the EARLY ACS trial of eptifibatide in 9492 patients with ACS.
Dr. Giugliano serves on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. He actively participates in the clinical activities of the Cardiovascular Division, attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and sees patients in a busy growing outpatient practice.
« Back to Editorial Board